|
Improved OA Pain Intensity and Patient's and Physician's Global Assessments of Disease Activity (ITT Population) |
|||
| Lumiracoxib 100 mg o.d. (n = 755) |
Lumiracoxib 100 mg b.i.d. (n = 1,519) |
Celecoxib 200 mg o.d. (n = 758) |
|
|
|
|||
| Patient's target joint pain intensity assessment |
|||
| Changes in scores from baseline to study endpoint, n (%)† |
|||
| Improvement |
382 (50.6) |
795 (52.3) |
406 (53.6) |
| No change |
269 (35.6) |
566 (37.3) |
265 (35.0) |
| Worsened |
104 (13.8) |
158 (10.4) |
87 (11.5) |
| Overall measure of efficacy, least squares mean‡ |
2.78 |
2.72 |
2.77 |
| Patient's global assessment of disease activity |
|||
| Changes in scores from baseline to study endpoint, n (%)† |
|||
| Improvement |
368 (48.7) |
768 (50.6) |
373 (49.2) |
| No change |
265 (35.1) |
534 (35.2) |
269 (35.5) |
| Worsened |
122 (16.2) |
216 (14.2) |
116 (15.3) |
| Overall measure of efficacy, least squares mean‡ |
2.61 |
2.54 |
2.60 |
| Physician's global assessment of disease activity |
|||
| Changes in scores from baseline to study endpoint, n (%)† |
|||
| Improvement |
411 (54.5) |
888 (58.5) |
425 (56.2) |
| No change |
244 (32.4) |
463 (30.5) |
232 (30.7) |
| Worsened |
99 (13.1) |
167 (11.0) |
99 (13.1) |
| Overall measure of efficacy, least squares mean‡ |
2.55 |
2.45* |
2.52 |
|
o.d. = once daily; b.i.d. = twice daily; ITT = intention-to-treat; †patients with missing baseline values were not included; ‡Overall measure of efficacy defined as the weighted average of post-baseline scores using the last observation carried forward technique for missing values and time since previous visit as weight (lower scores represent better responses); *p < 0.05 vs lumiracoxib 100 mg o.d. and celecoxib 200 mg o.d. | |||
Fleischmann et al. BMC Musculoskeletal Disorders 2008 9:32 doi:10.1186/1471-2474-9-32 |
|||